The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
Open accessAbstract
Background Satralizumab, a humanised monoclonal antibody targeting the interleukin-6 receptor, reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD) when added to immunosuppressant therapy. This study assessed the safety and efficacy of satralizumab monotherapy in patients with the disorder. Methods In this phase 3, double-blind, placebo-controlled, parallel-group trial, we enrolled adults aged 18-74 years with aquaporin-4 antibody seropositive or seronegative NMOSD at 44 investigational sites in 13 countries. Eligible participants had experienced at least one documented NMOSD attack or relapse in the past 12 months and had a score of 6·5 or less on the Expanded Disability Status Scale. Exclusion criteria included clinical relapse 30 days or fewer before baseline. Participants were randomly assigned (2:1) to receive satralizumab 120 mg or visually matched placebo subcutaneously at weeks 0, 2, 4, and every 4 weeks thereafter. Taking immunosuppressants concomitantly was prohibited. The primary endpoint was time to the first protocol-defined relapse, based on the intention-to-treat population and analysed with stratification for two randomisation factors (previous therapy for prevention of attacks and nature of the most recent attack). Safety was assessed in all participants who received at least one dose of satralizumab or placebo. The double-blind phase was due to last until 44 protocol-defined relapses occurred or 1·5 years after random assignment of the last patient enrolled, whichever occurred first; participants could enter an open-label phase after the occurrence of a protocol-defined relapse or at the end of the double-blind phase. The study is registered with ClinicalTrials.gov, NCT02073279. Findings 95 (57%) of 168 screened participants were randomly assigned to treatment (63 to satralizumab; 32 to placebo) between Aug 5, 2014, and April 2, 2017. Protocol-defined relapses occurred in 19 (30%) patients receiving satralizumab and 16 (50%) receiving placebo (hazard ratio 0·45, 95% CI 0·23-0·89; p=0·018). 473·9 adverse events per 100 patient-years occurred in the satralizumab group, as did 495·2 per 100 patient-years in the placebo group; the incidence of serious adverse events and adverse events leading to withdrawal was similar between groups. Interpretation Satralizumab monotherapy reduced the rate of NMOSD relapse compared with placebo in the overall trial population, with a favourable safety profile. The patient population included a ratio of aquaporin-4 antibody seropositive and seronegative patients that was reflective of clinical practice. Satralizumab has the potential to become a valuable treatment option for patients with NMOSD. Funding Chugai Pharmaceutical (Roche).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In any case, the long-term persistence of (re-)activatable autoantigen-specific ThEx cells in patients in remission may well explain the less-than-perfect treatment efficacy of steroid-sparing agents, 64-67 depletion of CD19/CD20 memory B cells, 68,69 as well as exacerbation of disease by b -IFN. 27,70”
From Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases (2024) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001729 · Cited by 4,649
Self-citationRevised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,568
Self-citationThe spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,182
Self-citation(2003) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-1-79 · Cited by 1,506
Interleukin-6, a Major Cytokine in the Central Nervous System
Erta, M., Quintana, A., & Hidalgo, J. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4679 · Cited by 1,093
Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
Pittock, S. J., Berthele, A., Fujihara, K., Kim, H. J., Levy, M., Palace, J. A., Nakashima, I., Terzi, M., Totolyan, N. A., Viswanathan, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900866 · Cited by 887
Physiological Roles of Aquaporin-4 in Brain
Nagelhus, E. A., & Ottersen, O. P. (2013) · Physiological Reviews · doi:10.1152/physrev.00011.2013 · Cited by 766
Cree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31817-3 · Cited by 756
Self-citationTrial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
Yamamura, T., Kleiter, I., Fujihara, K., Palace, J. A., Greenberg, B. M., Zakrzewska‐Pniewska, B., Patti, F., Tsai, C., Saiz, A., Yamazaki, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901747 · Cited by 663
Self-citationChihara, N., Aranami, T., Sato, W., Miyazaki, Y., Miyake, S., Okamoto, T., Ogawa, M., Toda, T., & Yamamura, T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017385108 · Cited by 476
Self-citation
Research works printed but not linked: 1
- Williamson M, McEnany M, Maxion-Bergemann S, Ong R. Epidemiologic temporal trends of neuromyelitis optic spectrum disorder in the United States from 2000 to 2015. 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Prague, Czech Republic; Aug 22–26, 2018.
Cited by
Sorted by citations
Items 201–300 of 513
Repulsive Guidance Molecule-A as a Therapeutic Target Across Neurological Disorders: An Update
Tseriotis, V.-S., Liampas, A., Lazaridou, I., Karachrysafi, S., Vavougios, G., Hadjigeorgiou, G., Papamitsou, T., Kouvelas, D., Arnaoutoglou, M., Pourzitaki, C., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073221 · Cited by 8
Capper, E. N., Linton, E. F., Anders, J. J., Kardon, R. H., & Gramlich, O. W. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03424-4 · Cited by 11
Relapse and disability outcomes in incident MOGAD patients undergoing watchful waiting after onset
Tisavipat, N., Wilf‐Yarkoni, A., Al-Ani, A., Costello, F., Kosiyakul, P., Jitprapaikulsan, J., Chirapapaisan, N., Schwartzmann, Y., Hellmann, M. A., Tolkovsky, A., et al. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106631 · Cited by 9
Uncommon inflammatory/immune-related myelopathies
Valencia-Sánchez, C., & Flanagan, E. P. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577750 · Cited by 9
Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents
Paolilo, R. B., da Paz, J. A., Apóstolos‐Pereira, S. L., Rimkus, C. D. M., Callegaro, D., & Sato, D. K. (2023) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0043-1761432 · Cited by 9
Fujihara, K., Kim, H. J., Saida, T., Misu, T., Nagano, Y., Totsuka, N., Iizuka, M., Kido, S., Terata, R., Okumura, K., et al. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104938 · Cited by 9
Interleukin-6 receptor blockade for the treatment of NMOSD
Levy, M. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30081-8 · Cited by 9
Asseyer, S., Masuda, H., Mori, M., Bellmann–Strobl, J., Ruprecht, K., Siebert, N., Cooper, G. A., Chien, C., Duchow, A. S., Schließeit, J., et al. (2021) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173211006862 · Cited by 9
“It has a significant effect on disease activity and is one of the most frequently used attack-preventive immunotherapies for NMOSD in Europe.2 Currently there are no controlled trials comparing the effect of long-time therapy with oral corticosteroids and rituximab in AQP4-IgG-positive NMOSD.”
BackgroundInfluentialCarlsson, O., Jónsson, D. I., Brundin, L., & Iacobaeus, E. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020355 · Cited by 8
Xue, B., Li, J., Xie, D., Weng, Y., Zhang, X., Li, X., Xia, J., & Lin, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1458556 · Cited by 8
Recommendations on NMOSD treatment in Latin America: Utilizing consensus-based RAND/UCLA methodology
Alonso, R. N., Rivera, V. M., Contentti, E. C., de Bedoya, V. F. H. D., Ciampi, E., Silva, B. A., Rodas, M. I. Z., Becker, J., Rojas, J. I., Gracia, F., et al. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2024.106244 · Cited by 8
Yamout, B. I., Gouider, R., Alroughani, R., Aljarallah, S., Shalaby, N., Al-Khabouri, J., Jacob, A., Inshasi, J. S. S., Mahdawi, A., Shatila, A. O., et al. (2026) · CNS Drugs · doi:10.1007/s40263-025-01260-x · Cited by 8
Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks
Rommer, P. S., Jiang, W., Nolte, J. P., Mikami, T., Seze, J. D., Sanchez, P., Harel, A., Alkabie, S., Kaneko, K., Bilodeau, P., et al. (2026) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200548 · Cited by 8
Self-citationWhat Is the Role of Dorsal Horn Astrocytes in Chronic Pain and Itch?
Benarroch, E. E. (2022) · Neurology · doi:10.1212/wnl.0000000000201505 · Cited by 9
“However, a phase-3, double-blind, placebo-controlled, parallel-group trial showed that satralizumab monotherapy reduced the rate of NMOSD relapse without such benefit in pain.(136,138) This emphasizes the complexity of the role of astrocytes and immune mechanisms in pain sensitization in the dorsal horn.”
BackgroundWingerchuk, D. M., Weinshenker, B. G., McCormick, D., Barron, S., Simone, L., & Jarzylo, L. A. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.12-a.s1 · Cited by 8
Self-citationA Clinical Approach to Existing and Emerging Therapeutics in Neuromyelitis Optica Spectrum Disorder
Yong, H. Y. F., & Burton, J. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01287-x · Cited by 8
Şen, S., Tuncer, A., Terzi, M., Bünül, S. D., Acar, N. P., Altunrende, B., Özakbaş, S., Tütüncü, M., Uygunoğlu, U., Akman‐Demir, G., et al. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104949 · Cited by 8
Golfinopoulou, R., Giudicelli, V., Manso, T., & Κοσσίδα, Σ. (2023) · Vaccines · doi:10.3390/vaccines11121756 · Cited by 8
Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics
Cacciaguerra, L., Tortorella, P., Rocca, M. A., & Filippi, M. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01055-0 · Cited by 9
“Subcutaneous satralizumab (120 mg at weeks 0, 2, 4, and every 4 weeks thereafter) was administered to NMOSD patients as add-on therapy [35] or as monotherapy [36] in two phase-III randomized placebo-controlled clinical trials.”
BackgroundMethodLow-dose tacrolimus in treating neuromyelitis optica spectrum disorder
Wang, L., Tan, H., Huang, W., ZhangBao, J., Chang, X., Zhou, L., Lü, C., Wang, M., Lu, J., Zhao, C., et al. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102707 · Cited by 8
What's new in neuromyelitis optica spectrum disorder treatment?
Chu, Y., & Huang, T. (2022) · Taiwan Journal of Ophthalmology · doi:10.4103/2211-5056.355617 · Cited by 8
“PREVENT and SAkuraSky allowed continuing prior immunosuppressive therapies, N‑MOmentum and SAkuraStar were conducted as monotherapies.”
MethodInfluentialAn update on biologic treatments for neuromyelitis optica spectrum disorder
Kim, W., & Kim, H. J. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2151441 · Cited by 8
“Infections were common in both treatment groups, and there was no evidence of an elevated risk of infection due to satralizumab [53,54].”
BackgroundCapobianco, M. A. N., Ringelstein, M., Welsh, C., Lobo, P., deFiebre, G., Lana–Peixoto, M. A., Wang, J., Min, J., & Wingerchuk, D. M. (2023) · Neurology and Therapy · doi:10.1007/s40120-022-00432-x · Cited by 8
Xie, Q., Sun, M., Sun, J., Zheng, T., & Wang, M. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9579 · Cited by 9
Therapeutic inertia in the management of neuromyelitis optica spectrum disorder
Cobo‐Calvo, Á., Gómez-Ballesteros, R., Orvíz, A., Sánchez, M. D., Boyero, S., Aguado-Valcárcel, M., Sepúlveda, M., Rebollo, P., López-Laiz, P., Mauriño, J., et al. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1341473 · Cited by 7
Greenberg, B. M., Fujihara, K., Weinshenker, B. G., Patti, F. P., Kleiter, I., Bennett, J. L., Palace, J. A., Blondeau, K., Burdeska, A., Ngwa, I., et al. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106444 · Cited by 7
Self-citationBennett, J. L., Fujihara, K., Saiz, A., Traboulsee, A. L., Greenberg, B. M., Weinshenker, B. G., Patti, F., Kleiter, I., Palace, J. A., Seze, J. D., et al. (2025) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200450 · Cited by 7
Self-citationImmunotherapies in neuromyelitis optica: Bayesian network meta-analysis
John, N. A., Lim, A., Sunthar, S. R., Zhang, L., Cheng, J., Boktor, J., Chong, V., Ma, H., & Phan, T. G. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13279-7 · Cited by 7
Kong, F., Wang, J., Zheng, H., Cai, H., Hua, J., & Li, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.652759 · Cited by 7
“Previous studies (Cree et al., 2019; Pittock et al., 2019; Yamamura et al., 2019; Traboulsee et al., 2020), as the present meta-analysis, support the use of monoclonal antibodies for AQP4-IgG-positive NMOSD.”
BackgroundMethodResultInfluentialXu, X., Xie, L., Wei, L., Li, M., Wang, H., Zhou, H., Sun, M., Yang, M. C., Xu, Q., Yang, K., et al. (2022) · Advances in Ophthalmology Practice and Research · doi:10.1016/j.aopr.2022.100064 · Cited by 7
Transitioning immunotherapy in neuromyelitis optica spectrum disorder – when and how to switch
Vishnevetsky, A., Kaplan, T., & Levy, M. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2145879 · Cited by 7
“When the data are combined, the reduction in risk of relapse is 62%, but a 79% reduction in relapse risk among AQP4-IgG-positive participants [14,30,31].”
BackgroundEvidence-based management of optic neuritis
Bergeron, É., & Bouffard, M. A. (2023) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000001007 · Cited by 7
Wildemann, B., Horstmann, S., Korporal‐Kuhnke, M., Viehöver, A., & Jarius, S. (2020) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1219-7907 · Cited by 7
“[84] Traboulsee A, Greenberg BM, Bennett JL et al.”
BackgroundPotential therapeutic strategies in chronic inflammatory demyelinating polyradiculoneuropathy
Hu, J., Zhao, C., & Lin, J. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103032 · Cited by 7
Luo, J., Yu, J., Sui, Z., Zhong, Y., Zheng, Q., & Li, L. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109004 · Cited by 7
Abboud, H., Steingo, B., Vargas, D. L., Patel, J. Y., Nealon, N., Willis, M. A., Mao‐Draayer, Y., Khaitov, D., Tsai, M., Kim, A. H., et al. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578585 · Cited by 6
“Furthermore, in clinical trials for FDA-approved NMOSD therapies, a mandatory washout period of 3 – 6 months was required before trial initiation for participants transitioning from rituximab (Yamamura et al., 2019; Traboulsee et al., 2020; Cree et al., 2019; Pittock et al., 2019).”
InfluentialEngels, D., Rocchi, C., Forcadela, M., Siriratnam, P., Ringelstein, M., Hümmert, M. W., Giglhuber, K., Berthele, A., Trebst, C., Aktaş, O., et al. (2025) · European Journal of Neurology · doi:10.1111/ene.70243 · Cited by 6
“Recently several approved monoclonal antibodies (inebilizumab, satralizumab, eculizumab, and ravulizumab) have become available for AQP4-IgG+ NMOSD treatment [9–12].”
Ochi, H., Nakamura, S., & Nakahara, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1635989 · Cited by 7
Advances in the therapeutic landscape for neuromyelitis optica spectrum disorder
Chamberlain, J. L., Siriratnam, P., & Huda, S. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2548947 · Cited by 6
“Satralizumab monotherapy in NMOSD was assessed in the parallel phase 3, randomized, double-blind, placebo-controlled trial – SAkuraStar study (NCT02073279) [41].”
Role of Tocilizumab in Severe CNS Inflammatory Presentations in Children
Marefi, A., Grasso, E. A., McLendon, L. A., Narula, S., Waldman, A. T., Hopkins, S. E., & Banwell, B. (2026) · Neurology · doi:10.1212/wnl.0000000000214926 · Cited by 6
New Treatment Perspectives for Acute Relapses in Neuromyelitis Optica Spectrum Disorder
Lotan, I., & Levy, M. (2022) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2022.06.008 · Cited by 6
Bennett, J. L., Fujihara, K., Kim, H. J., Marignier, R., O’Connor, K. C., Sergott, R. C., Traboulsee, A. L., Wiendl, H., Wuerfel, J. T., Zamvil, S. S., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1114667 · Cited by 7
Self-citationAbboud, H., Subei, A. M., Sengul, B., Shin, R. K., Goulette, P., Walch, R., Coté, J., Pace, R., Obeidat, A. Z., Ferayorni, L., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1526563 · Cited by 6
Wang, L., Du, L., Li, Q., Li, F., Wang, B., Zhao, Y., Meng, Q., Li, W., Pan, J., Xia, J., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.947974 · Cited by 6
Ponleitner, M., & Rommer, P. S. (2022) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-022-00987-2 · Cited by 7
Diagnostic criteria and treatment of neuromyelitis optica spectrum disorders (NMOSD)
Simaniv, T. O., Bakhtiyarova, K. Z., Belova, A. N., Goncharova, Z. A., Sivertseva, S. A., Спирин, Н. Н., Totolyan, N. A., Trushnikova, T. N., Turova, E. L., Хайбуллин, Т. И., et al. (2023) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2023-1s-71-75 · Cited by 9
Thon, J. M., Sharkus, R., Thakkar, R., Hunter, K. M., Siegler, J. E., & Thon, O. R. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.105076 · Cited by 6
Levy, M. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001382 · Cited by 6
Simaniv, T. O., Kochergin, I. A., Zakharova, M. N., Korobko, D. S., Zaslavsky, L. G., Зеленова, О. В., & Абрамов, С. И. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202112107196 · Cited by 6
Neurologic Therapeutics in 2035
Johnson, N. E., & Greene, E. P. (2021) · Neurology · doi:10.1212/wnl.0000000000012976 · Cited by 6
Neuromyelitis Optica Spectrum Disorders
Li, X., & McKeon, A. B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00024-5 · Cited by 6
Cree, B., Greenberg, B. M., Cameron, C., & Weinshenker, B. G. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00376-2 · Cited by 6
“Satralizumab, which targets the interleukin-6 receptor, was studied as monotherapy (SAkuraStar) and in combination with immunosuppressives (SAkuraSky) [4, 5].”
MethodSelf-citationVilaseca, A., Bilodeau, P., Gakis, G., Savransky, A., Oliveira, J. M. F., Nguyen, L., Hooshmand, S., Satyanarayan, S., Moseley, C. E., Haley, L., et al. (2026) · JAMA Neurology · doi:10.1001/jamaneurol.2026.2220 · Cited by 5
Self-citationPathomrattanapiban, C., Tisavipat, N., Jitprapaikulsan, J., Prayoonwiwat, N., Rattanathamsakul, N., & Siritho, S. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103882 · Cited by 5
James, J., Gafoor, V., Jose, J., Smita, B., & Balaram, N. (2023) · Journal of Neurosciences in Rural Practice · doi:10.25259/jnrp_59_2022 · Cited by 5
Mitoxantrone in NMO Spectrum Disorder in a Large Multicenter Cohort in French Caribbean
Chaumont, H., Bérard, N., Karam, J., Lobjois, Q., Tressières, B., Signaté, A., Lannuzel, A., & Cabre, P. (2023) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200175 · Cited by 5
Takahashi, Y., Kezuka, T., Shikishima, K., Yamagami, A., Chuman, H., Nakamura, M., Ueki, S., Kimura, A., Hashimoto, M., Tatsui, S., et al. (2024) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-024-01129-4 · Cited by 5
Chen, X., Wang, R., Li, R., Hu, S., Shi, Z., & Zhou, H. (2025) · Journal of Neurology · doi:10.1007/s00415-025-12937-0 · Cited by 5
Zhou, J., Yang, X., Wang, X., Li, B., Xu, Y., Zhang, H., Zhu, Y., Wang, X., & Feng, J. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1559118 · Cited by 5
Steinegger, L., Kana, V., Pot, C., Gobbi, C., Weller, M., Roth, P., Théaudin, M., Zecca, C., & Herwerth, M. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106602 · Cited by 5
Optic neuromyelitis after vaccination against SARS-CoV-2
Hernandez-Vega, M., Orozco-Narvaez, A., Reyes-Vaca, J. G., & Rodríguez‐Leyva, I. (2022) · BMJ Case Reports · doi:10.1136/bcr-2022-252309 · Cited by 5
Rectifying global inequities in neuromyelitis optica diagnosis and treatment
Mateen, F. J. (2023) · Multiple Sclerosis Journal · doi:10.1177/13524585231179108 · Cited by 5
Meher, B. R., Mohanty, R. R., & Dash, A. (2024) · Cureus · doi:10.7759/cureus.55100 · Cited by 5
Leisegang, R. F., Baumann, H. E. S., Lennon-Chrimes, S., Ito, H., Miya, K., Genin, J., & Plan, E. L. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13230 · Cited by 5
Isobe, N., Oda, T., Yamaguchi, T., Kamei, Y., Tsumuraya, T., Yuri, A., Nakasone, A., Asao, K., & Matsuda, S. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00794-y · Cited by 4
“…tract infection, acute pyelonephritis, and sepsis) and sites of infections (urinary and respiratory) noted in this study are aligned with the evidence provided by previous studies, namely a satralizumab clinical trial [10], a satralizumab real-world study [23], and rituximab studies [20–22].”
InfluentialKumar, P., Chaudhary, B., Devi, S., Dubey, G., Chatterjee, A., Sharma, D., & Gupta, M. M. (2025) · NeuroMarkers. · doi:10.1016/j.neumar.2025.100113 · Cited by 4
Lotan, I., Anderson, M., & Levy, M. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90887-0.00015-8 · Cited by 4
Innate immunity: current understandings and future perspectives
Zou, C., Ma, T., Li, J., & Zhou, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02920-0 · Cited by 8
Bradl, M., Yu, Q., & Takai, Y. (2025) · Seminars in Immunology · doi:10.1016/j.smim.2025.101945 · Cited by 7
Прахова, Л. Н., Сергеевич, К. В., Kasatkin, D. S., & Korobko, D. S. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202212207268 · Cited by 4
Funakoshi, K., & Suzuki, K. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06495-w · Cited by 4
Simaniv, T. O., Belkina, A. A., & Zakharova, M. N. (2023) · Annals of Clinical and Experimental Neurology · doi:10.54101/acen.2023.2.9 · Cited by 4
Measuring the economic burden of neuromyelitis optica spectrum disorder in Colombia
Gil-Rojas, Y., Amaya-Granados, D., Quiñones, J. A., Robles, A., Samacá-Samacá, D., & Hernández, F. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.105376 · Cited by 4
Rees, J., Rempe, T., Tuna, İ. S., Montalvo, M., Sabat, S. B., Massini, T. C., & Yetto, J. M. (2024) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/j.mric.2023.12.001 · Cited by 5
Successful Childbirth During Satralizumab Treatment in Neuromyelitis Optica Spectrum Disorder
Nakashima, S., Hao, A., Uchio, N., & Matsumoto, H. (2024) · Cureus · doi:10.7759/cureus.55010 · Cited by 4
“Clinical trials have demonstrated that satralizumab treatment significantly reduces the annualized relapse rate in patients with NMOSD [9,10], and satralizumab has FDA approval for NMOSD.”
BackgroundFluid Biomarkers in Demyelinating Spectrum Disorders: Past, Present, and Prospects
Florea, A.-M., Neațu, M., Luca, D.-G., Davidescu, E. I., & Popescu, B. O. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094455 · Cited by 4
“…centered on the implications of cytokines in the pathogenesis of demyelinating spectrum disorders, more specifically on targeting IL-6 (which is linked to the risk of relapses and higher EDSSs in patients with NMOSD), found that tocilizumab and satralizumab demonstrated clinical benefits [75–77].”
Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders
Gao, Y.-L., Zhang, B., & Yang, J. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020976669 · Cited by 4
Recent advances in the treatment of neuromyelitis optica spectrum disorders
Romeo, A. R. (2021) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000791 · Cited by 4
Du, Y., Li, K., Liu, W., Song, R., Luo, M., He, J., Xu, X., & Qu, X. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210329101335 · Cited by 4
Massacesi, L., Mariottini, A., & Nicoletti, F. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154288 · Cited by 4
“MAbs directed against IL-6 receptor and C5 showed high efficacy and an acceptable safety profile in phase 3 clinical trials [90,91].”
BackgroundUpdate on glial antibody-mediated optic neuritis
Song, H., Zhou, H., & Wei, S. (2022) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-022-00932-1 · Cited by 4
“1 3 results of 4 randomized, double-blind, placebo-controlled clinical trials, the United States Food and Drug Administration (FDA) approved eculizumab [55], ineblizumab [56], and satralizumab [57, 58] for the treatment of AQP4-NMOSD in adults.”
BackgroundTargeting B cell dysregulation with emerging therapies in autoimmune demyelinating disorders
Liyanage, G., & Brilot, F. (2022) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2022.102643 · Cited by 4
Las audiencias y la administración de justicia en las Indias
Martiré, E. (2005) · Universidad Autónoma de Madrid eBooks · Cited by 4
Interleukin-6 Immunology in Macrophage Activation Syndrome Related to Neuroimmunological Diseases
Nomura, T., Niino, M., Odani, T., Naganuma, R., Amino, I., Miyazaki, Y., Akimoto, S., Tanei, Z., Kimura, T., Minami, N., et al. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3757-24 · Cited by 3
“Furthermore, the anti-IL-6 receptor inhibitor satralizumab significantly prevents relapse (8).”
Huang, W., Lin, R., Zeng, X., Wang, H., & Yan, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1665688 · Cited by 4
Post marketing real-world experience of ravulizumab in NMOSD
Jacob, A., Mahmoud, A., Saab, R. R., Deif, A. A., Lee, G., Elhabet, S., Eldweik, L., Mifsud, V. A., Benedetti, B., & Shatila, A. O. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106747 · Cited by 3
Contentti, E. C., Boldrini, V. D. O., Vanegas, A. C., Gluščević, S. V., Koç, E. R., Samadzadeh, S., Seferoğlu, M., Szejko, N., & Levy, M. (2025) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2025.2565189 · Cited by 3
“In that context, the SC dose is 120 mg at weeks 0, 2, and 4, followed by maintenance dosing every four weeks [86,87].”
InfluentialYamamura, T., Isobe, N., Kawachi, I., Nohara, C., Miyazaki, Y., Tomita, M., Kamei, Y., Yamashita, K., Nakahara, J., Nakashima, I., et al. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00799-7 · Cited by 3
Self-citationNeuromyelitis optica spectrum disorder (NMOSD): Recent advances and insights from Taiwan
Yang, W.-Y. O., Lin, C., Yu, K.-W., Guo, Y., & Liao, Y. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.10.019 · Cited by 3
Aljarallah, S., Althobaiti, A., Abulaban, A. A., Aldosari, F. M., Alhasan, S., Ali, E. N., Alnajashi, H. A., Mutlaq, A. A., Althubaiti, I. A., Alyafeai, R., et al. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106847 · Cited by 4
Boldrini, V. D. O., & Contentti, E. C. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578817 · Cited by 3
Shi, Y., Li, Y., Xu, X., Liu, J., An, X., Zhang, M., Shen, Y., Pan, J., Jia, D., & Zhang, C. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106871 · Cited by 3
Role of B cells and pathogenic autoantibodies in autoimmune CNS and PNS neurologic diseases
Stathopoulos, P., & Dalakas, M. C. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90887-0.00003-1 · Cited by 5
The role of monoclonal antibodies against IL-6 or IL-6R in the treatment of thyroid eye disease
Ezra, D. G., Azumi, A., Briceño, C. A., Rajaii, F., Salvi, M., Sales‐Sanz, M., Brockwell, L., & Idowu, O. O. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-10014-5 · Cited by 3
Monoclonal Antibodies as Therapeutic Agents for Inflammatory Diseases
Bairos, J., Capela, E. V., Tavares, A. P. M., & Freire, M. G. (2021) · Frontiers in clinical drug research. Anti-infectives/Frontiers in clinical drug research. Anti infectives · doi:10.2174/9789815039412121080003 · Cited by 2
Chen, X., Xiao, J., Zhou, L., Yu, W., Chen, M., Chu, Y., Shang, K., Deng, G., Song, W., Qin, C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1135061 · Cited by 3
Monoclonal antibodies in neuro-ophthalmology
Keehn, C. C., Yazdian, A. T., Hunt, P. J., Davila-Siliezar, P. A., Laylani, N. A. R., & Lee, A. G. (2024) · Saudi Journal of Ophthalmology · doi:10.4103/sjopt.sjopt_256_23 · Cited by 3
“[72] Satralizumab is now the first IL‑6 receptor (IL‑6R) antagonist FDA approved for the treatment of NMOSD.”
BackgroundCao, Y., Zhang, J., & Wang, J. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04612-8 · Cited by 4
“Additionally, satralizumab, an anti-IL-6 receptor monoclonal antibody, works by inhibiting IL-6-mediated inflammatory responses and is applicable to both adults and adolescents with NMOSD, including cases with both AQP4-IgG − and AQP4-IgG + statuses [41, 42].”
Yamamura, R., Kinoshita, M., Yasumizu, Y., Yata, T., Kihara, K., Motooka, D., Shiraishi, N., Sugiyama, Y., Beppu, S., Murata, H., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1508977 · Cited by 3
Wang, Y., & Xu, Y. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106351 · Cited by 3
Metadata
- Authors
- Traboulsee, A., Greenberg, B. M., Bennett, J. L., Szczechowski, L., Fox, E., Shkrobot, S., Yamamura, T., Terada, Y., Kawata, Y., Wright, P., Gianella-Borradori, A., Garren, H., & Weinshenker, B. G.
- Affiliations
- University of British Columbia (CA)
- The University of Texas Southwestern Medical Center (US)
- University of Colorado Anschutz (US)
- Medical University of Silesia (PL)
- Central Texas Neurology Consultants (US)
- National Center of Neurology and Psychiatry (JP)
- Chugai Pharmaceutical Co., Ltd. (Japan) (JP)
- Genentech (US)
- Mayo Clinic (US)
- Corresponding author
- Traboulsee, Anthony
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 19
- Issue
- 5
- Pages
- 402-412
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC7935419
- OpenAlex
- W3018886418
- Cited by
- 513
- References
- 28
- Citations by year
- 2026: 79 · 2025: 86 · 2024: 75 · 2023: 68 · 2022: 91 · 2021: 80 · 2020: 32
- FWCI
- 44.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 356 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Neurology (acceptedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Bayer
- Mitsubishi Tanabe Pharma Corporation
- Teva Pharmaceutical Industries
- Genentech
- Guthy-Jackson Charitable Foundation
- Novartis
- Chugai Pharmaceutical
- Roche
- Japan Blood Products Organization
- National Multiple Sclerosis Society
- MedImmune
- Patient-Centered Outcomes Research Institute
- National Institutes of Health
- Biogen
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- satralizumab, neuromyelitis optica spectrum disorder, IL-6 receptor, monotherapy, relapse prevention, aquaporin-4 antibodies, seronegative NMOSD, Expanded Disability Status Scale, safety, efficacy, monoclonal antibodies, open-label extension, relapse rate, disability progression, treatment discontinuation, adverse events, immunosuppressants
- MeSH terms
- Adolescent, Adult, Aged, Double-Blind Method, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Neuromyelitis Optica, Treatment Outcome, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
